- Associated Press - Friday, November 13, 2015

WASHINGTON (AP) - The Food and Drug Administration has approved a new drug from AstraZeneca for patients with lung cancer that has spread despite earlier treatments.

The daily pill, Tagrisso, is intended for patients whose tumors have a genetic mutation that affects their growth.

Regulators approved the drug based on two studies of about 400 people that showed roughly 60 percent of patients treated with the drug had a partial or complete reduction of their tumor size.

The drug was approved under the FDA’s accelerated approval program, which grants streamlined market access based on promising early-stage results.

The FDA also approved an accompanying diagnostic to test for the mutation that Tagrisso targets.

Lung cancer is the most deadly form of cancer in the U.S., with an estimated 158,000 deaths expected in 2015.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.


Click to Read More

Click to Hide